News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets
French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration for the promotion and distribution of Dysport (abobotulinumtoxinA for Injection) in new territories.
The companies have renewed their collaboration in Brazil and Argentina for five years, effective January 1, 2013, and have extended their partnership to Australia where Galderma will have an exclusive five year promotion and distribution right to Dysport. In addition, both companies have signed an agreement to co-promote Dysport and Restylane in South Korea, which came into effect on November 23, 2012. Source: Company press release. Analysts at Credit Suisse have a net present value (ex-USA0 of 8.56 a share for Dysport (23% of total) for Ipsen.
Nimotuzumab assets change hands
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze